Table 1 Patient and tumor characteristics in all patients
Characteristic | SHERBOC no(n = 525) | SHERBOC yes(n = 125) |
|---|---|---|
Age at study entry (years) | 60.9 (13.1) | 61.1 (11.9) |
BMI (kg/m2) | 26.6 (5.9) | 26.0 (5.6) |
Time from diagnosis to metastasis (years) | 6.0 (6.5) | 6.9 (7.5) |
Tumor grade | ||
 1 | 38 (7.8) | 13 (12.5) |
 2 | 333 (68.4) | 75 (72.1) |
 3 | 116 (23.8) | 16 (15.4) |
ECOG score | ||
 0 | 251 (50.3) | 82 (67.8) |
 1 | 192 (38.5) | 33 (27.3) |
  ≥ 2 | 56 (11.2) | 6 (5.0) |
Concomitant diseases | ||
 0 or 1 | 242 (46.4) | 62 (50.4) |
 2 to 4 | 192 (36.8) | 46 (37.4) |
  ≥ 5 | 88 (16.9) | 15 (12.2) |
Metastasis pattern | ||
 Brain | 48 (9.2) | 4 (3.3) |
 Visceral | 237 (45.3) | 42 (34.1) |
 Bone | 88 (16.8) | 29 (23.6) |
 Other | 150 (28.7) | 48 (39.0) |
HRG test | ||
 Negative | – | 18 (47.4)a |
 Positive | – | 14 (36.8)a |
 Not evaluable | – | 6 (15.8)a |
Ever received chemotherapy | ||
 No | 279 (53.1) | 125 (100.0) |
 Yes | 246 (46.9) | 0 (0.0) |
Ever received endocrine therapy | ||
 No | 109 (20.8) | 12 (9.6) |
 Yes | 416 (79.2) | 113 (90.4) |
Ever received fulvestrant | ||
 No | 356 (67.8) | 125 (100.0) |
 Yes | 169 (32.2) | 0 (0.0) |
Previous CDK4/6i documented | ||
 No | 405 (77.1) | 4 (3.2)b |
 Yes | 120 (22.9) | 121 (96.8) |
SHERBOC line | ||
 1 | 290 (55.2) | 117 (93.6) |
 2 | 235 (44.8) | 8 (6.4) |